Summary & Overview
Skin Grafts and Wound Debridement for Endocrine, Nutritional and Metabolic Disorders with MCC: Inpatient Reimbursement Overview
DRG 622 encompasses inpatient admissions for skin grafting and wound debridement in the setting of endocrine, nutritional, and metabolic disorders with a Major Complication or Comorbidity. It defines a higher-weighted Diagnosis-Related Group used by Centers for Medicare & Medicaid Services to adjust Medicare inpatient reimbursement for complex surgical and medical resource use.
DRG 622 Overview
DRG 622 covers inpatient admissions involving skin grafts and extensive wound debridement for patients with underlying endocrine, nutritional, and metabolic disorders accompanied by a Major Complication or Comorbidity. Typical cases include diabetic patients or those with metabolic dysregulation requiring surgical wound management and resource-intensive perioperative care. This Diagnosis-Related Group matters for Medicare payment because it groups high-acuity surgical wound care with significant comorbidity burden, affecting reimbursement levels and hospital case-mix considerations.
Clinical Trials
- Acute surgical intervention trials investigating optimal debridement and grafting techniques for patients with endocrine, nutritional, and metabolic disorders complicated by severe soft-tissue infection or non-healing ulcers (for example, diabetic foot infections or necrotizing soft-tissue infections). These studies enroll hospitalized patients undergoing urgent wound debridement and skin grafting, comparing different operative approaches, timing of surgery, adjunctive intraoperative therapies, or perioperative infection-control protocols. Findings inform surgeons and hospital administrators about strategies that may reduce operative morbidity, length of stay, and resource utilization for this high-acuity DRG population.
- Comparative effectiveness studies of adjunctive biologic or advanced wound therapies in medically complex patients with metabolic disorders and large skin defects or chronic non-healing wounds. These trials typically include patients with comorbid diabetes, malnutrition, renal impairment, or obesity who require skin grafts or repeated debridements, and they compare outcomes such as graft take, need for reoperation, wound-related readmissions, and time to wound closure across dressings, negative-pressure therapy regimens, or cellular/biologic products. Results are relevant to payers and care managers evaluating cost-effectiveness, readmission risk, and durable healing outcomes to guide coverage decisions and bundled payment initiatives.
- Post-discharge outcomes and care-coordination research assessing rehabilitation, home health, and secondary prevention strategies in patients discharged after skin grafting and debridement for metabolic/endocrine-related wounds. These cohort or randomized pragmatic studies follow patients after hospital discharge to evaluate wound recurrence, functional status, glycemic/nutritional control, adherence to offloading and wound-care protocols, and utilization of outpatient services or readmissions. Evidence from these studies helps providers and payers design transitional care pathways and case-management programs that reduce readmissions and long-term costs while improving functional recovery in this medically complex population.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.